Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm Study to Assess the Safety and Immunogenicity of Omalizumab Liquid Administered Subcutaneously to Male and Female Adolescents and Adults With Persistent Allergic Asthma

NCT00500539 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00500539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00500539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm Study to Assess the Safety and Immunogenicity of Omalizumab Liquid Administered Subcutaneously to Male and Female Adolescents and Adults With Persistent Allergic Asthma
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
September 30, 2008
Enrollment
155 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

asthma